Phase 2 Non-Alcoholic Fatty Liver Disease (NCT04881760) This Phase 2A clinical trial was a sub-study of the Phase 2 clinical trial in obesity mentioned earlier, done for the purpose of measuring changes in liver fat and other associated biomarkers within people suffering from metabolic dysfunctionassociated steatotic liver disease (MASLD)
On review of pancreatic tissue from 36 patients undergoing partial pancreatectomy for PGBH, the pancreatic islet cells of the PGBH group were larger and more irregular compared with controls
That distinction matters, because most of the content out there is getting this wrong
At present, several oral antidiabetic medications are used for the treatment of T2DM including, -glucosidases inhibitors, biguanides, sulfonylureas, meglitinides, GLP-1 receptor agonists (GLP-1RAs), peroxisome proliferator-activated receptor (PPAR-) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodiumglucose transporter 2 (SGLT2) inhibitors
Do not worry about perfecting every detail immediately
